JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that the company will ring The Nasdaq Stock Market Opening Bell on Monday ...

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of. After Ligand last year created Pelthos Therapeutics to support the launch of Zelsuvmi, Pelthos is ...

EMERYVILLE, Calif. & NEW YORK--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Ligand) (NASDAQ: LGND) today announced the signing of a definitive merger agreement with Avista Public ...

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...

Researchers now offer a simplified method they call ProteinReDiff that uses artificial intelligence to speed the redesign of ligand-binding proteins. In biology, the binding of cellular proteins ...

Roivant Sciences has picked up the rights to Ligand Pharmaceuticals’ glucagon receptor antagonist LGD-6972. The midphase Type 2 diabetes candidate slots into the pipeline of Roivant’s newly ...